July 13, 2018

Announcements

Register Today for Closer to Free!

Our annual Closer to Free Ride is just 57 days away on Saturday, September 8! Please consider joining us on this amazing day of community for Smilow Cancer Hospital and Yale Cancer Center. There are several ways to be involved, either as a rider, volunteer, or supporter of the event, and 100% of the funds raised support patient care and research here! Each year, the event grows and our community and patients support us in amazing ways.

Take a few minutes to watch the video from last year's event to see just how wonderful the day is for all of us here at Smilow, Yale Cancer Center, and for our patients and families.

Learn more about the ride, volunteer opportunities, ways to donate, and how the 2017 funds made an impact!
Dr. Amer Zeidan has received a 2018 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute. The award supports outstanding clinical researchers at NCI-Designated Cancer Centers and recognizes outstanding mid-career clinical investigators.

Congratulations to Dr. Xavier Llor, who has been promoted to the rank of Professor of Medicine, Clinician-Educator. In addition to caring for patients with colorectal cancer in his clinical practice, Dr. Llor is Co-Director of the Cancer Genetics and Prevention Program and Medical Director of the Screening and Prevention Program.
Roy S. Herbst, MD, PhD is Co-Chair of the Sixth JCA-AACR Special Joint Conference on the Latest Advances in Lung Cancer Research: From Basic Science to Therapeutics in Kyoto, Japan this week.

CureSearch has awarded its inaugural Catapult Award to Dr. Ranjit Bindra to support his ground-breaking work on a novel drug for pediatric glioma through the launch of a new clinical trial. Dr. Bindra will partner with the Pacific Pediatric Neurology Oncology Consortium to administer the clinical trial at 18 pediatric cancer centers in the U.S., enrolling 45 patients.

Learn More >>

Development Update

After 24 years as a volunteer on the women's inpatient unit, Barbara Gaab recently had to stop because of her own illness. To commemorate her time at Yale and Smilow, Barbara recently donated two of her favorite art pieces to the unit during a celebration in her honor. Barbara had visited patients every week, bringing with her full-sized art reproductions of works that are found in the Yale University Art Gallery. Trained as a docent by the Art Gallery, her vision was to be both an ambassador for healing, as well as for the arts in New Haven. During her visits, Barbara would tell patients stories about the paintings, the artists, and the history of the times they depicted. She hoped that her visits would provide relief from the distress and boredom of illness and hospital admissions.

#SocialMediaPrimer: Do's and Don'ts for Cancer Docs Two oncologists share advice on using social media to improve patient care

Read More >>

Breast Cancer Survivor To Ride in Closer to Free One Year After Surgery

Read More >>

How obesity drives colon cancer in mice

Read More >>

New Centers to Advance Implementation and Prevention Sciences

Read More >>
Employee Profile: Fentyshia Daniels

Pay attention to the sun this summer and take time to protect yourself from the powerful summer rays! Learn more from the Smilow Screening and Prevention Program.

Join Yale Cancer Center on Facebook

Latest Posts:

Our CROY program for local students has kicked off for the summer! It provides young people from the community with hands-on cancer research experience and mentoring. The program is directed by Beth Jones, PhD, MPH, and is supported by a CURE supplement to the Yale Cancer Center Support Grant from the National Cancer Institute. Congratulations to these students on their selection to the program. We can't wait to see what you achieve!
Fentyshia Daniels, LMSW graduated from the University of Bridgeport with a Journalism degree that she originally intended to use to become a reporter. However, the impact of a mentor led her in a different direction, and she has parlayed the communication skills she gained as an undergraduate in college, along with her Master's degree in Social Work, into a impactful role counseling patients as a social worker for Yale Urology.

Fentyshia frequently works with patients in urologic oncology, helping them navigate the system, securing daily resources such as transportation for treatments and appointments, as well as providing support through the often emotional and physical journey that is cancer. She also sees patients in the areas of stone disease, urologic-gynecology (uro-gyn), and the gender-affirming surgery program. In these areas where most symptoms are generally not visible externally, feelings of patients are frequently minimized. Fentyshia steps in to help provide emotional validation and respect, and to let patients know someone is in their corner.

"Being the light in the fog and helping someone get back to completing their regular daily skills is meaningful to me," explains Fentyshia. "I want my patients to know they are not alone in this journey. They have a family at Yale and we are here to walk you through this process."

Fentyshia recently celebrated her one-year anniversary as a social worker at Yale New Haven Health, and she loves coming to work every day. "I have a great team - the doctors, nurses, techs, management - they are all supportive and we make a difference every single day."

**Funding Opportunities**

**YCCI Fund to Retain Clinical Scientists at Yale School of Medicine**
YCCI announces a request for applications for the FRCS. The goal of this exceptional program is to retain early-career physician-scientists in research.

**Application Deadline:** July 16, 2018  
[Learn More >>]

**Administrative Supplements to Support Tool and Resource Development to Address Racial and Ethnic Disparities in Multiple Myeloma**
This opportunity is a first step in addressing scientific research gaps in the field of multiple myeloma disparities research. Evaluation of this supplemental funding will help to inform future funding opportunities for multiple myeloma disparities research.

**Application Deadline:** July 22, 2018  
[Learn More >>]

**Collaborative Activities to Promote Cancer Cachexia Research**
The purpose of this supplement is to support collaborative, multidisciplinary basic and translational research that addresses an important question in cancer cachexia and to expand the cadre of investigators experienced in cancer cachexia study design, model systems and data interpretation.

**Application Deadline:** July 30, 2018  
[Learn More >>]

**Biden Cancer Initiative Fierce Awards**
The Biden Cancer Initiative is taking nominations for its inaugural FIERCE Awards, recognizing individuals and organizations making a transformative impact on the lives of cancer patients in five categories: prevention and early detection; reducing cancer disparities; patient navigation; survivorship; and LEAP (Leadership through Exemplary and Awesome Purpose).

**Nominations Due By:** July 31, 2018  
[Learn More >>]

**Susan G. Komen Career Catalyst Research Grant**
Susan G. Komen is seeking LOIs for outstanding translational research into the understanding, detection, and treatment of metastatic breast cancer which will lead to a reduction in breast cancer deaths by 2026.

**LOI Due:** August 1, 2018  
[Learn More >>]
Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low and Middle-Income Countries R21

The purpose of this FOA is to stimulate research on interventions to reduce HIV/AIDS-associated stigma and its impact on the prevention and treatment of HIV/AIDS and on the quality of life of People Living with HIV/AIDS.

Application Deadline: August 1, 2018
Learn More >>

HIV/AIDS and the Tumor Niche (R01)

The purpose of this FOA is to advance our understanding of the role of the tumor niche or microenvironment in the risks, development, progression, diagnosis, and treatment of cancer observed in individuals with an underlying HIV infection or AIDS.

Application Deadline: August 7, 2018
Learn More >>

DoD Prostate Cancer Research Program Opportunities

- **Idea Development Award:** This Award is intended to support new ideas that represent innovative approaches to prostate cancer research and have the potential to make an important contribution to the PCRP mission. **Pre-Application Deadline:** July 6, 2018
- **Impact Award:** This Award supports research projects that have the strong potential to make a major impact on scientific and clinical prostate cancer issues and is intended for independent investigators at or above the level of Assistant Professor (or equivalent). **Pre-Application Deadline:** July 19, 2018
- **Physician Research Award:** This Award supports a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in prostate cancer research. **Pre-Application Deadline:** August 16, 2018
- **Early Investigator Research Award:** This Award supports prostate cancer-focused research opportunities for individuals in the early stages of their careers, under the guidance of one or more designated Mentors. **Pre-Application Deadline:** August 16, 2018

Learn More >>

Calendar
Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (RO1/R21)
The purpose of the FOA is to advance our understanding of the modes of transmission of Kaposi sarcoma-associated herpesvirus; the biology of the initial steps of infection; and risk factors for infection in populations living with HIV or at high risk of developing HIV.

Application Deadline: August 18, 2018
Learn More >>

DoD Kidney Cancer Research Program Funding Opportunities for 2018

- **Concept Award:** To support highly innovative, untested, potentially groundbreaking concepts in kidney cancer. **Letter of Intent Due:** July 11, 2018
- **Idea Development Award:** To support new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer. **Letter of Intent Due:** September 5, 2018
- **Physicians Research Award:** To support a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in kidney cancer research. **Letter of Intent Due:** September 5, 2018
- **Technology Development Award:** To support emerging technologies to aid clinical and patient outcomes. **Letter of Intent Due:** September 5, 2018
- **Translational Research Partnership:** To support partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications. **Letter of Intent Due:** September 5, 2018

Learn More >>

NCI Community Oncology Research Program (NCORP)
This FOA solicits applications from institutions/organizations to participate as "Research Bases" for the National Cancer Institute (NCI)-supported Community Oncology Research Program (NCORP). There are three funding opportunities available:

- Research Bases (UG1 Clinical Trial Required)
- Community Sites (UG1 Clinical Trial Required)
- Minority/Underserved Community Sites (UG1 Clinical Trial Required)

Application Deadline: August 31, 2018
Learn More >>
Elsa U. Pardee Foundation Grant
The Elsa U. Pardee Foundation funds research to investigators in United States non-profit institutions proposing research directed toward identifying new treatments or cures for cancer.
**Application Deadline:** August 31, 2018
[Learn More >>](https://www.pardee.org)

**Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (R41/R42 and R43/R44)**
This FOA encourages both (R43/R44) Small Business Innovation Research and (R41/R42) Small Business Technology Transfer grant applications from small business concerns to develop or adapt, apply, and validate existing or emerging technologies into user-friendly products for cancer prevention, diagnosis, or treatment in low-resource settings.
**Application Deadline:** September 5, 2018
[Learn More >>](https://www.pardee.org)

**Gilead Sciences Research Scholars Program in Hematology/Oncology**
Grants of up to $130,000 over two years will be awarded to junior faculty researchers for innovative translational research projects in hematology/oncology (with a focus on hematologic malignancies) that can be either based around a clinical trial with strong correlative science or laboratory investigation.
**Application Deadline:** September 7, 2018
[Learn More >>](https://www.pardee.org)

**"High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R01/R21)**
The purpose of this FOA is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency (HIV) infection or AIDS.
**Application Deadline:** September 7, 2018
[Learn More >>](https://www.pardee.org)

**HIV and Hepatitis B Co-Infection: Advancing HBV Functional Cure through Clinical Research (R01/R21)**
The purpose of this FOA is to fill scientific gaps needed to (a) inform HBV functional cure strategies by furthering our understanding of unique challenges impacting HBV and HIV co-infected hosts and (b) advance the discovery and development of novel HBV interventions that are safe and achieve a functional cure in HIV and HBV co-infected individuals.
**Application Deadline:** September 7, 2018
[Learn More >>](https://www.pardee.org)

---

**Smilow Art Therapy Summer Thursdays**
July 26; 4PM
NP4-101A
[Learn More >>](https://www.hms.harvard.edu)

**Submissions**
Please submit your recent publication and grant announcements to:

Renee Gaudette
Director, Public Affairs and Communications

[Learn More >>](https://www.hms.harvard.edu)
In Vitro and Animal Model Studies on HBV/HIV Co-Infection (R01/R21)
The purpose of this FOA is to stimulate and accelerate development of novel in vitro and small animal models of HBV/HIV co-infection and create a better understanding of the immunopathogenic interactions between HBV and HIV.

**Application Deadline:** September 7, 2018

[Learn More >>](#)

Harnessing Big Data to Halt HIV (R01)
The purpose of this FOA is to promote research that transforms understanding of HIV transmission, the HIV care continuum, and HIV comorbidities using Big Data Science.

**Application Deadline:** September 7, 2018

[Learn More >>](#)

### Recent Publications

**Ablation versus Resection for Stage 1A Renal Cell Carcinoma: National Variation in Clinical Management and Selected Outcomes.**
Uhlig J, Kokabi N, Xing M, Kim HS.
[Read More >>](#)

**Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report.**
Han C, Bellone S, Schwartz PE, Govindan SV, Sharkey RM, Goldenberg DM, Santin AD.
[Read More >>](#)

**RES complex is associated with intron definition and required for zebrafish early embryogenesis.**
Fernandez JP, Moreno-Mateos MA, Gohr A, Miao L, Chan SH, Irimia M, Giráldez AJ.
[Read More >>](#)

**Oligosaccharyltransferase inhibition Reduces Receptor Tyrosine Kinase Activation and Enhances Glioma Radiosensitivity.**
Baro M, Lopez Sambrooks C, Quijano A, Saltzman WM, Contessa JN.
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia.

Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Johnson SB, Yu JB.

Fear of Mastectomy Associated with Delayed Breast Cancer Presentation Among Ghanaian Women.
Martei YM, Vanderpuye V, Jones BA.

The Objective of Local Therapy in Oligometastatic Cancer Is a Moving Target.
Boffa DJ.

Regional Practice Patterns and Racial/Ethnic Differences in Intensity of End-of-Life Care.
Wang SY, Hsu SH, Huang S, Doan KC, Gross CP, Ma X.
Health Serv Res. 2018 Jun 27.